治疗前HBV DNA水平预测HBV/HCV合并感染患者抗HCV治疗后的长期乙肝应答
该研究纳入192例接受聚乙二醇干扰素治疗的HBV/HCV合并感染患者,随访平均68.8个月。治疗前HBV DNA水平300 IU/mL是所有结局的独立预测因素,联合HCV应答可增强对HBV flare和HBsAg清除的预测。
要点
- 治疗前HBV DNA 300 IU/mL是HBV flare和HBsAg清除的独立预测因素。
- 平均随访68.8个月,26.6%患者出现HBV DNA≥2000 IU/mL。
- 联合治疗前HBV DNA和HCV应答可提高预测能力。
核心结论
- 治疗前HBV DNA水平300 IU/mL可预测抗HCV治疗后HBV flare和HBsAg血清清除。
研究设计与样本
- 研究纳入192例接受聚乙二醇干扰素治疗的HBV/HCV合并感染患者,随访平均68.8个月。
主要发现
- 4例(2.1%)患者在治疗结束前出现早期HBV再激活。
- 仅19例(10.1%)出现ALT flare并接受口服HBV抗病毒治疗,风险为1.7/100人年。
- 67例(34.9%)患者实现HBsAg血清清除,概率为5.7/100人年。
- 治疗前HBV DNA水平300 IU/mL是所有结局的独立预测因素,联合HCV应答进一步增强预测。
关键数值与推荐
- HBV DNA≥2000 IU/mL作为结局指标之一,伴或不伴ALT≥2倍正常上限。
- HBsAg血清清除作为结局指标。
- 治疗前HBV DNA水平300 IU/mL为独立预测因素。
临床怎么用
- 对于HBV/HCV合并感染患者,抗HCV治疗前应检测HBV DNA水平。
- 治疗前HBV DNA水平300 IU/mL可用于风险分层,预测HBV flare和HBsAg清除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to investigate the long-term outcomes in hepatitis B (HBV)/hepatitis C virus (HCV) dual-infected patients after anti-HCV therapy. METHODS: A total of 192 HBV/HCV dual-infected patients who had received pegylated interferon treatment were recruited. The investigation outcomes included HBV DNA ≥2000 IU/mL, with or without alanine aminotransferase (ALT) ≥2-fold the upper limit of normal, and hepatitis B surface antigen (HBsAg) seroclearance. RESULTS: Four (2.1%) patients developed early HBV reactivation before the end of treatment. Fifty (26.6%) of the remaining patients had an episode of HBV DNA ≥2000 IU/mL in a mean follow-up of 68.8 months. The risk was 4.6 per 100 person years. Only 19 (10.1%) patients developed concomitant ALT flare with oral HBV antiviral therapy; the risk was 1.7 per 100 person years. Despite HBV flare, 67 (34.9%) patients had a favorable outcome of HBsAg seroclearance. The probability was 5.7 per 100 person years. A pretreatment HBV DNA level of 300 IU/mL served as an independent predictor for all the outcomes. The combined pretreatment HBV DNA level and HCV response further enhanced the prediction of HBV flare and HBsAg seroclearance. CONCLUSIONS: A pretreatment HBV DNA level of 300 IU/mL predicts HBV flare and HBsAg seroclearance after anti-HCV therapy.
引用
- Yeh ML, Huang CI, Huang CF, et al. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. J Infect Dis. 2019. PMID: 30452671. doi:10.1093/infdis/jiy648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。